Pelacarsen Fails to Cut CV Events; Metformin Cuts Long COVID Risk

New trial data presented at the American Heart Association meeting shows that lowering lipoprotein(a) with pelacarsen failed to reduce major cardiovascular events, while a target trial emulation study finds metformin prescribed within six days of COVID-19 diagnosis cuts long COVID risk by roughly half.

The pelacarsen results, published in the New England Journal of Medicine, upend a long-standing hypothesis that reducing Lp(a) — a genetically determined, atherogenic lipoprotein — would translate into fewer heart attacks, strokes, or revascularizations. Over a median 4.7 years, 4,100 patients receiving monthly subcutaneous injections achieved a 70% reduction in Lp(a) levels yet experienced no difference in the composite primary endpoint compared with placebo, MedPage Today reported.

“We know that when you reduce cardiovascular risk factors, the more that you reduce, the better outcome you get,” said Rick Lange, MD, president of Texas Tech Health El Paso, on the TTHealthWatch podcast. “But apparently, it doesn’t appear to be so.”

In contrast, the metformin analysis, published in Clinical Infectious Diseases, leveraged electronic health records to emulate a randomized trial. Researchers at the University of Minnesota compared new metformin users — 248 patients prescribed the drug within six days of SARS-CoV-2 infection — against controls prescribed fluvoxamine, fluticasone, ivermectin, or montelukast.

Long COVID or death occurred in 4% of the metformin group versus 8.5% of controls, a relative risk reduction of roughly half. “There’s pretty convincing data that it reduces the risk of long COVID symptoms by about 50%,” Lange told MedPage Today. “I would be inclined to offer it to the patient.”

Pelacarsen Fails to Cut CV Events; Metformin Cuts Long COVID Risk
Photo: happeningnow.news

Pelacarsen Failed; Early Metformin Cut Long COVID

  • Lp(a) lowering alone is not enough: Pelacarsen slashed lipoprotein(a) levels by 70% but did not prevent heart attacks, strokes, or cardiovascular death in a high-risk cohort already on standard preventive therapy.
  • Early metformin shows promise for long COVID: Starting the diabetes drug within six days of a positive COVID-19 test was associated with a halving of long COVID diagnoses or death in a real-world emulation study.
  • Trial design matters: The Lp(a) data come from a gold-standard randomized controlled trial; the metformin data come from an observational emulation study, which cannot prove causation but supports prior randomized trial findings.

Pelacarsen Flops in Phase 3 Outcomes Trial

The Lp(a) HORIZON trial enrolled patients with established atherosclerotic cardiovascular disease and Lp(a) levels above 70 nmol/L. Participants received pelacarsen 80 mg subcutaneously every four weeks or matching placebo.

Despite a mean reduction in Lp(a) at six months — sustained through follow-up — the hazard ratio for the primary composite endpoint (coronary heart disease death, myocardial infarction, stroke, or urgent coronary revascularization) was 1.04 (95% CI, 0.89–1.21). Subgroup analyses by baseline Lp(a) tertiles also showed no benefit.

Investigators speculated that concurrent intensive lipid-lowering therapy — most patients were on statins, many on ezetimibe, and some on PCSK9 inhibitors — may have compressed the residual risk window. “Maybe the delta just wasn’t high enough to show up,” Elizabeth Tracey, director of electronic media for Johns Hopkins Medicine, noted on the podcast. Two other Lp(a)-lowering agents, olpasiran and lepodisiran, are in late-stage testing; results are expected in 2026 and 2027, respectively.

Novartis Heart Drug Pelacarsen Cuts Lp(a) 78% But Fails 5-Year Trial — Signal Brief

Metformin Emulation Study Validates COVID-OUT Signal

The University of Minnesota team, led by Carolyn T. Bramante, MD, MPH, and David R. Boulware, MD, MPH, used a sequential target trial emulation design to minimize immortal time bias — a flaw where patients must survive long enough to receive treatment, artificially inflating benefit.

They required a clinic visit in the six months before and after infection, excluded anyone with a metformin or control prescription in the prior year, and matched on propensity scores.

The primary outcome — a clinician-documented long COVID diagnosis or death — occurred in 10 of 248 metformin recipients (4%) versus 21 of 248 controls (8.5%). The hazard ratio was 0.47 (95% CI, 0.22–0.99).

This aligns with the COVID-OUT randomized trial, where metformin started within three days of symptom onset reduced long COVID by 63% (HR 0.37, 95% CI, 0.15–0.95) and the overall trial population saw a 41% reduction (HR 0.59, 95% CI, 0.39–0.89). A mechanistic substudy found metformin accelerated viral clearance: time to undetectable SARS-CoV-2 RNA was 3.3 days versus 5.6 days with placebo (P=0.043).

Novartis Heart Drug Pelacarsen Cuts Lp(a) 78% But Fails 5-Year Trial #Shorts — Signal Brief

Mechanistic Divergence: Why Lp(a) Lowering Failed Where Metformin Succeeded

Lp(a) carries oxidized phospholipids that promote foam-cell formation, endothelial dysfunction, and thrombosis. Antisense oligonucleotides like pelacarsen reduce hepatic synthesis of apolipoprotein(a), the defining protein of Lp(a).

Yet the HORIZON result suggests Lp(a) may be a risk marker rather than a modifiable causal mediator in patients already on maximal lipid-lowering therapy. Mendelian randomization studies support causality, but pharmacological lowering late in the disease course may not reverse established plaque.

Metformin’s antiviral and anti-inflammatory actions are distinct. The drug activates AMPK, inhibits mTOR, and reduces mitochondrial reactive oxygen species, impairing viral replication. In vitro, metformin reduced SARS-CoV-2 viral load by 93.2% versus 78.3% for placebo (P=0.013).

It also dampens NLRP3 inflammasome activation and TFEB-mediated lysosomal biogenesis, pathways implicated in post-viral fatigue syndromes. The emulation study’s active comparators — fluvoxamine (sigma-1 agonist), fluticasone (corticosteroid), ivermectin (antiparasitic), montelukast (leukotriene antagonist) — shared no common mechanism, strengthening the specificity argument.

Pelacarsen Stays Investigational; Metformin Is Generic

Pelacarsen remains investigational; Ionis Pharmaceuticals and Novartis have not announced regulatory filing plans pending the ongoing OCEAN(a) outcomes trial (NCT05581303) in patients with higher baseline Lp(a) and recurrent events.

Metformin, by contrast, is generic, costs pennies per dose, and is on the WHO Essential Medicines List. The FDA has not approved any indication for long COVID prevention. Off-label prescribing is legal but requires shared decision-making. The CDC’s clinical guidance for post-COVID conditions does not yet mention metformin.

The American Heart Association, founded in Chicago in 1924 by six cardiologists as a professional society, marked a turning point in 1949 when a nationwide radio contest called The Walking Man raised $1.5 million from over two million listeners. The influx funded the first large-scale research program and, since then, the organization has invested more than $6.1 billion in cardiovascular, cerebrovascular, and brain health research.

Contraindications & When to Consult a Doctor

  • Metformin: Contraindicated in eGFR <30 mL/min/1.73 m², acute heart failure with hypoxia, or known hypersensitivity. Caution in hepatic impairment, alcohol use disorder, and age >80 without renal monitoring. Common adverse effects: gastrointestinal upset (diarrhea, nausea), vitamin B12 deficiency with long-term use.
  • Pelacarsen: Not approved for clinical use. Injection-site reactions occurred in 18% of recipients.
  • Clinical action: Patients with a new COVID-19 diagnosis and no contraindications may discuss a short course of metformin (typically 500 mg daily titrated to 1,500 mg over three days, then continued for 14 days per COVID-OUT protocol) with their clinician. Do not self-prescribe. Seek urgent care for worsening dyspnea, chest pain, or confusion during acute infection.

“I would take it for sure,” Tracey told Lange when asked if she would accept metformin for a new COVID diagnosis. “I would also not…” — her sentence trailing off as the podcast ended, leaving the clinical community awaiting guideline updates and the next Lp(a) trial readouts.

References

  • Lp(a) HORIZON Trial. New England Journal of Medicine. 2024.
  • Bramante CT, et al. Preventing Long COVID With Metformin: A Target Trial Emulation. Clinical Infectious Diseases. 2026;72(5):e423–e432. DOI: 10.1093/cid/ciaf700
  • Bramante CT, et al. Outpatient Treatment of COVID-19 With Metformin (COVID-OUT). New England Journal of Medicine. 2023.
  • TTHealthWatch Podcast Transcript. MedPage Today. November 2024.
  • ClinicalTrials.gov. OCEAN(a) Trial (NCT05581303). National Library of Medicine.
Photo of author

Health Desk

Health Desk at Archyde.

Pop Culture Still Can’t Figure Out Drone Warfare, Foreign Policy Reports